Summit Therapeutics Inc. Deferred Tax Expense Income
Summit Therapeutics Inc. (SMMT) reported Deferred Tax Expense Income of GBP 148.00 thousand for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2020-06-02
- Summit Therapeutics Inc. deferred tax expense income for the quarter ending 2020-03-31 was 148.00K GBP.
- Summit Therapeutics Inc. deferred tax expense income for the quarter ending 2019-10-31 was -31.00K GBP.
- Summit Therapeutics Inc. deferred tax expense income for the quarter ending 2019-07-31 was -32.00K GBP.
- Summit Therapeutics Inc. deferred tax expense income for the quarter ending 2019-04-30 was -31.00K GBP.
| Period end | Deferred Tax Expense Income 3 month | Deferred Tax Expense Income 6 month | Deferred Tax Expense Income 9 month | Deferred Tax Expense Income 11 month | Deferred Tax Expense Income 12 month | Deferred Tax Expense Income 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-03-31 | 148.00K GBP 6-K · filed 2020-06-02 | |||||
| 2019-12-31 | -115.00K GBP 20-F · filed 2020-04-30 | |||||
| 2019-10-31 | -31.00K GBP 6-K · filed 2019-12-17 | -63.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | -94.00K GBP 6-K · filed 2019-12-17 | |||
| 2019-07-31 | -32.00K GBP 6-K · filed 2019-10-11 | -63.00K GBP 6-K · filed 2019-10-11 | ||||
| 2019-04-30 | -31.00K GBP 6-K · filed 2019-06-12 | |||||
| 2019-03-31 | -31.00K GBP 6-K · filed 2020-06-02 | |||||
| 2019-01-31 | -32.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -139.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | -704.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | -704.00K GBP 20-F · filed 2020-04-30 | 704.00K GBP 20-F · filed 2019-03-29 | |
| 2018-10-31 | -107.00K GBP 6-K · filed 2019-12-17 | -672.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | -672.00K GBP 6-K · filed 2019-12-17 | -672.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-07-31 | -565.00K GBP 6-K · filed 2019-10-11 | -565.00K GBP 6-K · filed 2019-10-11 | -565.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | -565.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-04-30 | 0.00 GBP 6-K · filed 2019-06-12 | 0.00 GBP derived: sum of 2 quarters · filed 2020-04-30 | 0.00 GBP derived: sum of 3 quarters · filed 2020-04-30 | 0.00 GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-01-31 | 0.00 GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 0.00 GBP derived: sum of 2 quarters · filed 2020-04-30 | 0.00 GBP derived: sum of 3 quarters · filed 2020-04-30 | 0.00 GBP 20-F · filed 2020-04-30 | ||
| 2017-10-31 | 0.00 GBP 6-K · filed 2018-12-11 | 0.00 GBP derived: sum of 2 quarters · filed 2018-12-11 | 0.00 GBP 6-K · filed 2018-12-11 | |||
| 2017-07-31 | 0.00 GBP 6-K · filed 2018-09-20 | 0.00 GBP 6-K · filed 2018-09-20 | ||||
| 2017-01-31 | 100.00K GBP 20-F · filed 2019-03-29 | |||||
| 2016-01-31 | 0.00 GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |